Here’s Why The Market Hates GlaxoSmithKline plc, But Loves Shire plc

GlaxoSmithKline plc (LON:GSK) and Shire plc (LON:SHP) are different value propositions, but Glaxo could do well if it executes a more aggressive strategy, writes Alessandro Pasetti.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) rose modestly this week following upbeat quarterly results and news that the drugs maker was considering a spin-out of ViiV Healthcare, its HIV medicines business. Glaxo also announced disposals of unwanted assets. Its stock is up about 6% this year, but has been outperformed by Shire by almost two percentage points. Here’ s why investors will likely continue to pay up for Shire (LSE: SHP), while Glaxo may be the laggard in 2015, although decent capital gains should be on the cards. 

Shire Rocks 

As I also argued in early January, when Shire traded at 4,560p, I’d add Shire to a diversified portfolio if I wanted exposure to the pharma industry. In fact, Shire is very likely to outperform both Glaxo and AstraZeneca for some time, based on several factors, in my view. I am attracted to Shire because it has been much more aggressive than its rivals in its corporate strategy, as its latest purchase of NPS Pharmaceuticals signals. Shire is exploiting its balance sheet at a time other pharma players have been more cautions managing their finances — at least until now. 

The average price target from brokers has risen by 60% in the last 12 months, and it looks like the shares may continue to rally, particularly since they currently price in only a small takeover premium in the region of 3%/5%, according to my calculation. At 4,947p, the stock trades at about 16x forward earnings. It is not incredibly cheap, but is not expensive, either. Of course, you wouldn’t buy Shire now for its dividend prospects. 

More To Come At Glaxo?

Glaxo has all it takes be an attractive equity investment, but for the time being it’s just a boring dividend play. Its recent deal with Novartis and its conservative corporate strategy bring more questions than answers, as banking sources have recently pointed out

Quarterly results were decent — just. Revenues from its troubled respiratory portfolio should return to growth next year, although market conditions are tough in the US. Glaxo announced on Wednesday it had agreed to sell on the market a 7.9% stake in Danish cancer drug developer Genmab for about $300m, which is a step in the right direction following its partnership with Novartis. 

But investors need more to pay up for the stock.  

“GlaxoSmithKline has taken the first firm step towards a partial spin-off of its HIV drugs business by appointing investment banks to advise on what would potentially be the biggest initial public offering in pharmaceuticals industry history,” the Financial Times reported on Wednesday.

Banking sources have confirmed the report, suggesting the spin-off could be arranged sooner than expected, however, and “possibly as early as this year,” according to one banker involved in the deal. “If the markets are stable, expect Glaxo to be pushed by its bankers to float the unit between the third and fourth quarter.”  

Personally, I think that the division could easily be worth more than $20bn.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »